Geoffrey Hall - Concepedia

Author

Geoffrey Hall

St James's University Hospital

Also Known As

G D Hall, G Hall, G. D. Hall, G. Hall, G.D. Hall, Geoffrey D Hall, Geoffrey D. Hall, Geoffrey Hall, R Edmondson

Publications

1.6K

Citations

H-Index

Concepts

All Affiliations

St James's University Hospital University of Leeds Cancer Research UK Westmead Hospital The University of Sydney

About

Geoffrey Hall is an author at St James's University Hospital specializing in medicine, cell biology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	349
2	Cell Biology	4	4	188
3	Pathology	3	3	293
4	Immunology	2	2	154
5	Obstetrics	1	1	27

Geoffrey Hall

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
Transforming growth factor- <i>beta</i> is a potent immunosuppressive agent that inhibits IL-1-dependent lymphocyte proliferation. Sharon M. Wahl, D A Hunt, H.L.S. Wong, The Journal of Immunology	1988	389
Human Tumour Immune Evasion via TGF-β Blocks NK Cell Activation but Not Survival Allowing Therapeutic Restoration of Anti-Tumour Activity Erica Wilson, Jehan J. El‐Jawhari, Abbie L. Neilson, PLoS ONE	2011	159
Uroplakin Gene Expression by Normal and Neoplastic Human Urothelium E. Dawn Lobban, Barbara A. Smith, Geoffrey Hall, American Journal Of Pathology	1998	137
Immunohistochemistry for PMS2 and MSH6 alone can replace a four antibody panel for mismatch repair deficiency screening in colorectal adenocarcinoma Geoffrey Hall, Adele Clarkson, Amanda Shi, Pathology Antibody PanelOncologyMedicineImmunologyPathology	2010	134
Uroplakin gene expression in normal human tissues and locally advanced bladder cancer Jonathon Olsburgh, Patricia Harnden, Robert J. Weeks, The Journal of Pathology UrologyUroplakin Gene ExpressionNormal Human TissuesAdvanced Bladder CancerUrinary Tract	2002	132
Proteomic Profiling Identifies Afamin as a Potential Biomarker for Ovarian Cancer David Jackson, Rachel A. Craven, Richard Hutson, Clinical Cancer Research	2007	95
A phase II study of interferon‐α, interleukin‐2 and 5‐fluorouracil in advanced renal carcinoma: clinical data and laboratory evidence of protease activation Johnathan Joffe, Rosamonde E. Banks, M A Forbes, British Journal of Urology	1996	78
Predicting Response to Bevacizumab in Ovarian Cancer: A Panel of Potential Biomarkers Informing Treatment Selection Fiona Collinson, Michelle Hutchinson, Rachel A. Craven, Clinical Cancer Research	2013	72
Phase I and Pharmacokinetic Study of Intravenous Irinotecan Plus Oral Ciclosporin in Patients With Fluorouracil-Refractory Metastatic Colon Cancer John Chester, Simon P. Joel, S L Cheeseman, Journal of Clinical Oncology	2003	48
A Phase 2, Randomized, Open-Label Study of Irosustat Versus Megestrol Acetate in Advanced Endometrial Cancer Patricia Pautier, Ignace Vergote, Florence Joly, International Journal of Gynecological Cancer	2016	38

Page 1